Earnings call transcript: Alkermes beats Q3 2026 estimates as sales rise
Alkermes outperformed market expectations in its third quarter 2026 results, reporting adjusted earnings of $0.09 per share and revenue of $480.1 million, surpassing analyst forecasts of a $0.08 loss and $463.35 million in revenue. The stock rose 1.8% in premarket trading to $45.70, indicating investor approval of the strong earnings beat.
Proprietary product sales increased 31% year over year, driven by VIVITROL, ARISTADA, LYBALVI, and LUMRYZ, which all achieved solid quarterly sales. Management highlighted a growing orexin pipeline with late-stage work on narcolepsy and new studies on ADHD, depression, and fatigue. Despite the positive earnings and revenue results, the market reaction was relatively muted, suggesting some expectations of the positive news.
Alkermes reaffirmed its full-year 2026 outlook, expecting nearly $1.6 billion in proprietary product portfolio net sales and maintaining guidance for VIVITROL, ARISTADA, LYBALVI, and LUMRYZ. The company expects lower cost of goods sold in 2027 as inventory accounting rolls off, while R&D spending is anticipated to rise as more studies advance.
The focus remains on the orexin portfolio, with management expecting multiple readouts in various neuropsychiatry areas.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
